<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781584</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-384-3914</org_study_id>
    <nct_id>NCT02781584</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of
      selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic
      fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohorts 1-6 and 9 will be enrolled sequentially while Cohorts 7 and 8 will be randomized in parallel. Cohorts 10 and 11 will be randomized in parallel. New cohorts 12 and 13 will be randomized in parallel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 24 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Up to 24 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Laboratory Abnormalities</measure>
    <time_frame>Up to 24 weeks plus 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>SEL (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Firsocostat (2 x 10 mg capsules) for 12 weeks
Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilofexor (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilofexor (3 x 10 mg tablets) for 12 weeks
Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL+ Cilofexor(Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL + Firsocostat(Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) + firsocostat (1 x 20 mg tablet) for 12 weeks
Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat + Cilofexor(Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat Cirrhotic (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Firsocostat (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)
Enrollment into Cohorts 7 and 8 will be randomized in parallel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilofexor Cirrhotic (Cohort 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilofexor (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)
Enrollment into Cohorts 7 and 8 will be randomized in parallel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL + Firsocostat + Cilofexor (Cohort 9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) + Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 9 will begin upon completion of enrollment for Cohort 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat + Fenofibrate 48 mg (Cohort 10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment with fenofibrate 48 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 48 mg tablet) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat + Fenofibrate 145 mg (Cohort 11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment with fenofibrate 145 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 145 mg tablet) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment with Vascepa® (2 x 1 g tablet twice daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + Vascepa® (2 x 1 g tablet twice daily) for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment with fenofibrate (1 x 145 mg tablet once daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + fenofibrate (1 x 145 mg tablet once daily) for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>SEL (Cohort 1)</arm_group_label>
    <arm_group_label>SEL + Firsocostat + Cilofexor (Cohort 9)</arm_group_label>
    <arm_group_label>SEL + Firsocostat(Cohort 5)</arm_group_label>
    <arm_group_label>SEL+ Cilofexor(Cohort 4)</arm_group_label>
    <other_name>GS-4997</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firsocostat</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>Firsocostat (Cohort 2)</arm_group_label>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)</arm_group_label>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)</arm_group_label>
    <arm_group_label>Firsocostat + Cilofexor(Cohort 6)</arm_group_label>
    <arm_group_label>Firsocostat + Fenofibrate 145 mg (Cohort 11)</arm_group_label>
    <arm_group_label>Firsocostat + Fenofibrate 48 mg (Cohort 10)</arm_group_label>
    <arm_group_label>Firsocostat Cirrhotic (Cohort 7)</arm_group_label>
    <arm_group_label>SEL + Firsocostat + Cilofexor (Cohort 9)</arm_group_label>
    <arm_group_label>SEL + Firsocostat(Cohort 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilofexor</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>Cilofexor (Cohort 3)</arm_group_label>
    <arm_group_label>Cilofexor Cirrhotic (Cohort 8)</arm_group_label>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)</arm_group_label>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)</arm_group_label>
    <arm_group_label>Firsocostat + Cilofexor(Cohort 6)</arm_group_label>
    <arm_group_label>SEL + Firsocostat + Cilofexor (Cohort 9)</arm_group_label>
    <arm_group_label>SEL+ Cilofexor(Cohort 4)</arm_group_label>
    <other_name>GS-9674</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)</arm_group_label>
    <arm_group_label>Firsocostat + Fenofibrate 145 mg (Cohort 11)</arm_group_label>
    <arm_group_label>Firsocostat + Fenofibrate 48 mg (Cohort 10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vascepa</intervention_name>
    <description>Administered orally two times daily</description>
    <arm_group_label>Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males and females between 18-75 years of age (Cohorts 1-9: 18-75 years and Cohorts
             10-13: ≥ 18 years); inclusive based on the date of the screening visit

          -  Willing and able to provide informed consent prior to any study specific procedures
             being performed

          -  Meets the following conditions (Cohorts 1-6 and 9):

               -  Clinical diagnosis of non-alcoholic fatty liver disease and evidence of F2-3
                  fibrosis

          -  For Cohorts 7 and 8, participants must have a clinical diagnosis of NAFLD and
             cirrhosis

          -  For Cohorts 10 and 11, individuals must have a clinical diagnosis of NAFLD and meet
             one of the following criteria :

               -  a) A historical liver biopsy within 6 months of Screening consistent with NASH
                  and bridging fibrosis (F3) or within 12 months of Screening consistent with NASH
                  and compensated cirrhosis (F4) in the opinion of the investigator,

               -  b) Screening liver stiffness by MRE ≥ 3.64 kPa;

               -  c) Screening liver stiffness by FibroScan® ≥ 9.9 kPa;

          -  For Cohorts 12 and 13, subjects must have a clinical diagnosis of NAFLD/NASH and one
             of the following criteria:

               -  a) At least two criteria for metabolic syndrome

               -  b) Historical liver biopsy consistent with NASH within 6-12 months of Screening

               -  c) Historical MRE with liver stiffness ≥ 2.88 kPa within 6 months of Screening

               -  d) Historical FibroScan® with liver stiffness ≥ 9.9 kPa within 6 months of
                  Screening,

        Key Exclusion Criteria:

          -  Pregnant or lactating females

          -  Other causes of liver disease including autoimmune, viral, and alcoholic liver disease

          -  Any history of decompensated liver disease, including ascites, hepatic encephalopathy
             or variceal bleeding

          -  For Cohorts 7-8, 10-13, Child-Pugh-Turcotte (CPT) score &gt; 6

          -  History of liver transplantation

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics (SHC)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners, LLC</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research, PLLC</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Firsocostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

